Skip to main content
An official website of the United States government


Placeholder slot

Talquetamab-tgvs works by bringing healthy T cells (immune cells that help kill cancer cells) and myeloma cells close together so the T cells can more effectively kill the the myeloma cells. It does this by binding to a protein called CD3 on healthy T cells and a protein called GPRC5D on myeloma cells. Talquetamab-tgvs is a type of targeted therapy drug called a bispecific T-cell engager (BiTE).

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Talquetamab-tgvs is approved to treat:

Talquetamab-tgvs is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Talquetamab-tgvs is only available as part of a special program called Tecvayli and Talvey REMS (Risk Evaluation and Mitigation Strategies).

More About Talquetamab-tgvs

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Talquetamab-tgvs - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Talquetamab-tgvs - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: